October 2016

Welcome to the PM Buzz with the latest headlines in personalized medicine and the latest news, content and events from the Diaceutics Group.
Latest News in Personalized Medicine

PRIME Launched by EMA to Speed Review and Approval of Innovative, “Breakthrough” Drugs read on...
Vice President Biden Delivers Cancer Moonshot Report, Announces Public and Private Sector Actions to Advance Cancer Moonshot Goals read on...
FDA approved atezolizumab (TECENTRIQ) for the treatment of patients with metastatic NSCLC read on...
HTG, Merck KGaA Ink CDx Development Deal for Lymphoma Drug read on...
FDA modified the indication for erlotinib (TARCEVA) read on...
FDA gives Roche’s Ventana PD-L1 assay approval in lung cancer treatment read on...
Thermo, Pfizer, Novartis Ready CDx Assay for FDA Submission read on...
Celgene and Agios team up with Abbott to develop companion diagnostic tests for certain leukemia patients read on...
Tesaro to Pursue PARP Inhibitor Indication in Overall Recurrent Ovarian Cancer Without Myriad CDx read on...
Amid Challenges of Studying Precision Oncology, Experts Continue Trying to Measure Impact read on...
Survey reveals inequalities in access to new, life saving drugs for melanoma in Europe read on...
VeriStrat® Test Identifies Patients with Squamous Cell Carcinoma of the Lung Who Are More Likely to Have Improved Survival on Afatinib Therapy read on...
Long-term Follow-up Confirms Safety of Imatinib Discontinuation in CML read on...
FDA Grants Breakthrough Therapy Designation for Genentech's Alecensa® (Alectinib) for First-Line Treatment of People with ALK-Positive NSCLC read on...
ICER on PD-1 Immunotherapies to Treat Lung Cancer: Lower the Prices read on...
NICE issues negative draft guidance on Merck's Keytruda read on...
Samsung Bioepis races rivals as EMA accepts Herceptin biosim app read on...
Pancreatic Cancer Action Network Unveils Precision Medicine Clinical Trial read on...
FDA Grants Roche Label Extension for the cobas® EGFR Mutation Test v2 for use with Plasma as a Companion Diagnostic for TAGRISSO™ read on...
Amgen's multiple myeloma drug falls short in new-patient study read on...
Syros Pharmaceuticals (SYRS) Doses First Patient in SY-1425 Phase 2 in AML, MDS with genetically defined populations read on...
Top scientists cautious about curing cancer with immunotherapy read on...
Novartis' Zykadia trial meets primary endpoint read on...
Yale researchers compare efficacy of four PD-L1 assay tests read on...
This month in Diaceutics News

[Media Mention] Illumina, Genentech and BIO Weigh in on FDA Draft Guidance on Companion Diagnostics read on...
[Expert Insight] How to Introduce Laboratories to a Diagnostic Scenario on Tropical Diseases that will Lead to a Better Diagnostic Pathway read on...
[Expert Insight] Feedback on IASLC Molecular Testing Guideline for Selection of Lung Cancer Patients – Revision 2016 Draft Recommendations read on...
[Webinar] Which Pharma Companies Are Ready For Precision Medicine in 2017: Benchmarking, Financial Risks and Predictions, December 12th 2016 read on...

[Webinar] How Can Analytics Help Avoid the PD-L1 Chaos: 10 Years of Insights read on...


     

© 2016 Diaceutics Group. All rights reserved.
Not interested? Unsubscribe | Update profile | Interested Subscribe | Impressed? Tell-A-Friend
Diaceutics | Belfast - New York